Patients with Gene Mutations Have Increased Risk …4 Mutations in BRCA2 have been associated with...
2
Better understand their cancer risk Help them take steps to lower their risk for getting BREAST, OVARIAN, PROSTATE or OTHER CANCERS Help them find it at an early stage when it’s easier to treat BRCA1 BRCA2 33% of men with a BRCA1/2 mutation had a diagnosis of cancer. 1 Identifying individuals, including men, “at risk of carrying a BRCA1/2 mutation can be LIFE- SAVING and should be a part of routine medical care.” 3 BRCA1 BRCA2 50% of women who inherit a mutation will develop Breast Cancer by age 70. 2 2019 USPSTF Recommendation for Genetic Testing AMA Policy Encourages Genetic Testing Under the Guidance of a Physician Knowledge Enables Action: 1) Ancestry associated with BRCA1/2 mutations 2) Women with prior cancers (Breast, Ovarian, Peritoneal and Fallopian Tube) Excluding men at risk of BRCA-associated cancers is a missed opportunity. 4 Mutations in BRCA2 have been associated with approximately a 3- to 8.6-fold increase in the risk for prostate cancer in various studies. BRCA1 mutations increase risk by up to almost 4 fold. 5 Genetic Testing for Hereditary Cancer Risk GENETICS DIVISION BRCA1 BRCA2 Increased Risk for Hereditary Cancer # T a k e A c t i o n Patients with Gene Mutations Have
Transcript of Patients with Gene Mutations Have Increased Risk …4 Mutations in BRCA2 have been associated with...
Better understand their cancer risk
Help them take steps to lower their risk for getting BREAST, OVARIAN, PROSTATE or OTHER CANCERS
Help them find it at an early stage when it’s easier to treat
BRCA1BRCA2
33% of men with aBRCA1/2 mutation hada diagnosis of cancer.1
Identifying individuals, including men, “at risk of carrying a BRCA1/2 mutation can be LIFE-SAVING and should be a part of routine medical care.” 3
BRCA1BRCA2
50% of women who inherita mutation will develop
Breast Cancer by age 70.2
2019 USPSTF Recommendationfor Genetic Testing
AMA Policy Encourages Genetic Testing Under the Guidance of a Physician
Knowledge Enables Action:
1) Ancestry associated with BRCA1/2 mutations
2) Women with prior cancers (Breast, Ovarian, Peritoneal and Fallopian Tube)
Excluding men at risk of BRCA-associated cancers is a missed opportunity. 4
Mutations in BRCA2 have been associated with approximately a 3- to 8.6-fold increase in the risk for prostate cancer in various studies. BRCA1 mutations increase risk by up to almost 4 fold. 5
Genetic Testing for HereditaryCancer RiskG E N E T I C S D I V I S I O N
BRCA1BRCA2
Increased Risk for Hereditary Cancer#TakeAction
Patients with Gene Mutations Have
G E N E T I C S D I V I S I O N
MD Labs Direct
Please Contact Your MD Labs Representative TodayMD LABS GENETIC TESTINGFOR HEREDITARY CANCER RISK
775-391-5221
1 Male BRCA mutation carriers: clinical characteristics and cancer spectrum, Mohammed Ibrahim, etal, BMC Cancer. 2018; 18:179.2 CDC Division of Cancer Prevention and Control³ Susan Domchek, MD; Mark Robson, MD JAMA Editorial August 2019.4 Rachel Yung (UW) and Larissa Korde (National Cancer Institute) JAMA Oncology editorial on the USPSTF recommendations, critical of the exclusion of men from the guidelines.5 The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families, Robert Pilarski, MS, MSW, Asco Educational Book, 2019; 79:86.
When Is Genetic Testing forHereditary Cancer Indicated?
Strong family history of certain types of cancer
Already diagnosed with cancer to determine if they are at higher risk for other cancers
Family member of a person known to have an inherited gene mutation that increases cancer risk
Per CMS, genetic testing is warranted when thereare signs or symptoms of cancer.
MD LabsA Trusted PartnerComprehensive Next Generation Sequencing Technology from AdvaGenix evaluates a panelof 138 inherited genes including BRCA1, BRCA2, Lynch Syndrome Genes, and other genes associatedwith an increased risk of leading cancers:
Report from Genetic Counselor with every test* Understand specific cancer risk factors* Understand treatment and medical management
Computerized Screening Technology incorporates AMA and insurance carrier guidelines to determine patient eligibility and insurance coverage
* Helps identify patients who will benefit from testing with likely insurance coverage
Insurance adjudication and direct patient payments managed by MD Labs* Simplifies process for patients and staff
Simple cheek sponge and secure online requisition process* Streamlined collection and submission process
Choose option 9
BREAST
OVARIAN
UTERINE
COLORECTAL
PANCREAS
GASTRIC
PROSTATE
mdlabs.com/cgx
